IONS — Ionis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $7.33bn
- $7.19bn
- $943.71m
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
US RESEARCH ROUNDUP-Boeing, Twilio, WP Carey
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Ionis Pharma tumbles after heart drug fails late-stage trial
Novartis, Ionis' experimental heart drug misses key goal in closely watched trial (updated)
Ionis-Novartis heart drug misses main goal of late-stage trial
U.S. STOCKS ON THE MOVE-Lululemon, Tesla, Planet Labs
U.S. STOCKS ON THE MOVE-Bank7, UiPath, gold miners
U.S. STOCKS ON THE MOVE-AMC Entertainment, Planet Labs, Robinhood Markets
U.S. STOCKS ON THE MOVE-Lululemon Athletica, Adobe, Ionis Pharmaceuticals
Ionis Pharma up after US FDA approves rare brain disorder treatment